Statin vs. LDL Goal Therapy for Older Adults with Diabetes
Part of Hormones & metabolism clinical trials.
This trial compares two approaches to lower cholesterol in people aged 70+ with type 2 diabetes: a moderate statin dose versus adjusting treatment to reach a personalized LDL-C target. It aims to find which strategy better prevents heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 70 years or older
- Have type 2 diabetes or take diabetes medication
- No history of heart disease, stroke, or peripheral artery disease
- Either not on cholesterol medicine with LDL above 100 mg/dL, or already on cholesterol medicine (any LDL level)
- No active cancer, severe frailty, or liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether taking a low- to moderate-dose statin can prevent first-time heart and stroke problems in people age 70 and older. It may help you lower “bad cholesterol” (LDL) and see if that leads to fewer heart events over time.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
This trial compares two cholesterol-lowering approaches in people with prediabetes to see which one is less likely to lead to new-onset diabetes. It may help you choose a safer medication plan if you need strong cholesterol treatment to prevent future heart problems.
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
This trial compares a high-dose combination of rosuvastatin (a statin) and ezetimibe (another cholesterol-lowering drug) versus a standard rosuvastatin-only approach for people with peripheral artery disease (narrowed leg arteries) or widespread artery disease. The goal is to see which strategy better lowers LDL cholesterol and reduces heart and limb risks.
This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.
Hear when a new Dyslipidemia Associated With Type II Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.